Although tremendous strides have been made in the treatment of melanoma, there is still much work to be done. At Roswell Park we offer several clinical research studies focused on the discovery and advancement of promising therapies to treat this most dangerous form of skin cancer. These studies are improving care for many of our patients, providing them new options and new hope.
In the above video, I describe some of these ongoing clinical research studies. You can also click these links to learn more:
- Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
- A Prospective, Multicenter, Randomized, Open-Label, Active-Controlled, Two-Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/day to Dacarbazine in the Treatment of Patients with Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
- A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node